{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:56Z","timestamp":1753892156759,"version":"3.41.2"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Malignant mesothelioma (MMe) is a rare neoplasm with few therapeutic options available. The landscape of effective therapy for this disease remained unchanged in the last two\u00a0decades. Recently, however, the introduction of Immune Checkpoint Inhibitors (ICIs) led to small, but nevertheless, promising improvements. However, many efforts are still needed to radically improve the prognosis of MMe. In this review, we analyze all those therapeutic strategies for MMe that are still in a preclinical or early clinical phase of development. In particular, we focus on novel antiangiogenic drugs and their possible combination with immunotherapy. Furthermore, we describe also more complex strategies such as microRNA-loaded vectors, oncolytic viruses, and engineered lymphocytes.<\/jats:p>","DOI":"10.3389\/fphar.2021.809337","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:59:59Z","timestamp":1639565999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Glimpse in the Future of Malignant Mesothelioma Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Gaetano","family":"Pezzicoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Minei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41416-021-01547-y","article-title":"Efficacy of CDK4\/6 Inhibitors in Preclinical Models of Malignant Pleural Mesothelioma","volume":"125","author":"Aliagas","year":"2021","journal-title":"Br. J. Cancer"},{"key":"B3","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2018.36.15_suppl.3080","article-title":"Safety and Efficacy Results from a Phase I Dose-Escalation Trial of Nintedanib in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (PEMBIB Trial)","volume":"36","author":"Andreea","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final Analyses of OPTiM: a Randomized Phase III Trial of Talimogene Laherparepvec versus Granulocyte-Macrophage colony-stimulating Factor in Unresectable Stage III-IV Melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/cancers13102332","article-title":"Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma","volume":"13","author":"Anobile","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B6","first-page":"4833","article-title":"Expression of Vascular Endothelial Growth Factor in Malignant Mesothelioma","volume":"26","author":"Aoe","year":"2006","journal-title":"Anticancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/s0140-6736(20)32714-8","article-title":"First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): a Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with Pemetrexed in Advanced Mesothelioma: a Multi-Institutional Experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res. Notes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Anti-tumor Activity in Solid Malignancies","volume":"2","author":"Beatty","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.surg.2013.06.004","article-title":"An Oncolytic Vaccinia Virus Expressing the Human Sodium Iodine Symporter Prolongs Survival and Facilitates SPECT\/CT Imaging in an Orthotopic Model of Malignant Pleural Mesothelioma","volume":"154","author":"Belin","year":"2013","journal-title":"Surgery"},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13148-018-0517-9","article-title":"Assessment of New HDAC Inhibitors for Immunotherapy of Malignant Pleural Mesothelioma","volume":"10","author":"Bensaid","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest Developments in Our Understanding of the Pathogenesis of Mesothelioma and the Design of Targeted Therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in Patients with Malignant Mesothelioma: a Phase II Trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for Malignant Pleural Mesothelioma after Radiotherapy (SMART): Final Results from a single-centre, Phase 2 Trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC Inhibitor Panobinostat (LBH589) Inhibits Mesothelioma and Lung Cancer Cells In Vitro and In Vivo with Particular Efficacy for Small Cell Lung Cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic Herpesvirus Therapy for Mesothelioma - A Phase I\/IIa Trial of Intrapleural Administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized Study of Maintenance Pemetrexed versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients with Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients with Malignant Pleural Mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria Monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4161\/15384047.2014.956605","article-title":"The Vascular Disrupting Agent BNC105 Potentiates the Efficacy of VEGF and mTOR Inhibitors in Renal and Breast Cancer","volume":"15","author":"Inglis","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ijc.23949","article-title":"Genomic Events Associated with Progression of Pleural Malignant Mesothelioma","volume":"124","author":"Ivanov","year":"2009","journal-title":"Int. J. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"01670","DOI":"10.1016\/j.athoracsur.2021.08.054","article-title":"Inhibition of CDK4\/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma","author":"Jang","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","article-title":"Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma","volume":"19","author":"Kanteti","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00268-019-05132-6","article-title":"Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA","volume":"43","author":"Keshava","year":"2019","journal-title":"World J. Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in Patients with Advanced Malignant Pleural Mesothelioma Who Have Progressed on Previous Chemotherapy (VANTAGE-014): a Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"key":"B32","first-page":"466","article-title":"Use of a \"Replication-Restricted\" Herpes Virus to Treat Experimental Human Malignant Mesothelioma","volume":"57","author":"Kucharczuk","year":"1997","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2019.12.018","article-title":"A Phase II Trial of Single Oral FGF Inhibitor, AZD4547, as Second or Third Line Therapy in Malignant Pleural Mesothelioma","volume":"140","author":"Lam","year":"2020","journal-title":"Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and Survival with GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic Measles Viruses Encoding Interferon Beta and the Thyroidal Sodium Iodide Symporter Gene for Mesothelioma Virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41416-020-0912-9","article-title":"Impact of Hypoxia on Chemoresistance of Mesothelioma Mediated by the Proton-Coupled Folate Transporter, and Preclinical Activity of New Anti-LDH-A Compounds","volume":"123","author":"Li Petri","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B37","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.1200\/JCO.2020.38.15_suppl.9058","article-title":"Safety and Efficacy of Tazemetostat, an Enhancer of Zeste-Homolog 2 Inhibitor, in Patients with Relapsed or Refractory Malignant Mesothelioma","volume":"38","author":"Marjorie","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as Second- or Third-Line Palliative Therapy in Malignant Pleural Mesothelioma: an International, multi-centre, Single-Arm, Phase II Trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A Phase II Clinical Trial of the Vascular Disrupting Agent BNC105P as Second Line Chemotherapy for Advanced Malignant Pleural Mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with First-Line Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma (DREAM): a Multicentre, Single-Arm, Phase 2 Trial with a Safety Run-In","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the Global burden of Mesothelioma Deaths from Incomplete National Mortality Data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup. Environ. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The Role of MicroRNAs in Human Cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal. Transduct Target. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without Ramucirumab as Second-Line Treatment for Malignant Pleural Mesothelioma (RAMES): a Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A Multicentre Randomised Phase III Trial Comparing Pembrolizumab versus Single-Agent Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-Meso Trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1016\/S1470-2045(21)00666-5","article-title":"RAMES Study: Is There Really a Role of VEGF-Inhibition in Mesothelioma?","volume":"22","author":"Porta","year":"2021","journal-title":"Lancet Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1158\/2159-8290.CD-21-0331","article-title":"Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma","volume":"11","author":"Raghav","year":"2021","journal-title":"Cancer Discov."},{"key":"B48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells with High-Schlafen 11 and Low-O6-Methylguanine-DNA Methyltransferase Expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring Expression of miR-16: a Novel Approach to Therapy for Malignant Pleural Mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for Malignant Pleural Mesothelioma: an International Guidelines Review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab Plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells","volume":"15","author":"Santamar\u00eda Nu\u00f1ez","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e24326","DOI":"10.1200\/JCO.2018.36.15","article-title":"CDK4\/6 Inhibitor and Radiation Therapy in Malignant Pleural Mesothelioma","volume":"36","author":"Seiji","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.21873\/anticanres.14140","article-title":"Hypoxia Inducible Factor-1\u03b1 Inhibition in Von Hippel Lindau-Mutant Malignant Pleural Mesothelioma Cells","volume":"40","author":"Shukuya","year":"2020","journal-title":"Anticancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/1535-7163.MCT-18-0708","article-title":"Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation","volume":"18","author":"Singh","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A Phase I, Pharmacokinetic and Pharmacodynamic Study of GSK2256098, a Focal Adhesion Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/mutage\/ger020","article-title":"Asbestos Exposure Affects poly(ADP-Ribose) Polymerase-1 Activity: Role in Asbestos-Induced Carcinogenesis","volume":"26","author":"Tomasetti","year":"2011","journal-title":"Mutagenesis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural Pneumonectomy versus No Extra-pleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma: Clinical Outcomes of the Mesothelioma and Radical Surgery (MARS) Randomised Feasibility Study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as Second-Line Treatment for Patients with Small-Cell Lung Cancer: a Single-Arm, Open-Label, Phase 2 Basket Trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemotherapy-Na\u00efve Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and Activity of microRNA-Loaded Minicells in Patients with Recurrent Malignant Pleural Mesothelioma: a First-In-Man, Phase 1, Open-Label, Dose-Escalation Study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cells8091091","article-title":"Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity","volume":"8","author":"Vlacic","year":"2019","journal-title":"Cells"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/jnci\/djaa002","article-title":"The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma-An Institutional and National Analysis","volume":"112","author":"Voigt","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for Newly Diagnosed Pleural Mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in Pemetrexed-Pretreated Patients with Malignant Pleural Mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.809337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:00:18Z","timestamp":1639566018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.809337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":67,"alternative-id":["10.3389\/fphar.2021.809337"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.809337","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"809337"}}